{
  "claim_id": "claim_000",
  "claim": "Flublok Quadrivalent is approved for adults 18 years and older.",
  "document": {
    "pdf_name": "FlublokPI"
  },
  "extraction_result": {
    "success": true,
    "total_snippets_found": 3
  },
  "extracted_evidence": [
    {
      "id": "comp_1",
      "quote": "Flublok is approved for use in persons 18 years of age and older. (1)",
      "relevance_explanation": "This quote explicitly states the approval age for Flublok, confirming it is for persons 18 years and older.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "Study 7 (NCT02290509) enrolled subjects 18 through 49 years of age randomized to receive Flublok Quad rival ent or a Comparator in activated influenza vaccine (Fluarix\u00ae Quad rival ent, manufactured by Glaxo smith kline). The safety analysis population included 998 recipients of Flublok Quad rival ent and 332 Comparator vaccine recipients.",
      "relevance_explanation": "This quote shows that Flublok Quadrivalent was studied and administered to adults aged 18 through 49, supporting its approval for adults 18 years and older.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_3",
      "quote": "Flublok quad rival ent has been administered to and safety data collected from 4328 adults 0 years of age and older (Study 61) and 998 adults 18-49 years of age (Study 72).",
      "relevance_explanation": "This quote provides data on the administration of Flublok Quadrivalent to adults 18 years and older, supporting its approved use in this age group.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ]
}